Europe Cervical Cancer Test Market: Cervical cancer is the disease caused by abnormal growth of the cervical cells in the cervix. Cervical cancer is most commonly occurs in women owing to genital Human Papilloma Virus (HPV) infection. It is the most common type of cancer in women and the symptoms in early stages are very low, however, the vaginal bleeding after menopause and pelvic pain are the symptoms shown in a later stage. Cervical cancer can be diagnosed by HPV testing, Pap smear testing, and colposcopy among others.
Europe Cervical Cancer Test Market:
Increase in the prevalence of cervical cancer in Europe region, growing the geriatric female population, and rise in awareness about the cervical cancer screening methods are anticipated to fuel the Europe cervical cancer test market. Furthermore, initiatives were taken by the government and various organizations for the prevention and control of cervical cancer, increase in incidence rate of HPV infections, and launching of low-cost Visual Inspection with Acetic acid (VIA) tests are driving the Europe cervical cancer test market. However, stringent regulatory guidelines, lack of early-stage symptoms, lack of reimbursement policies for disease diagnosis, and underdeveloped healthcare infrastructure are the factors restraining the Europe Cervical Cancer Test Market.
Europe Cervical Cancer Test Market is segmented on the basis of test type and end user
Based on the test type, Europe Cervical Cancer Test Market is segmented into the following:
- Pap smear tests
- Endocervical curettage
- Human Papilloma Virus (HPV) testing
- Visual Inspection with Acetic acid (VIA) testing
Based on the end user, Europe Cervical Cancer Test Market is segmented into the following:
- Oncology centres
- Diagnostic Centres
Europe Cervical Cancer Test Market is growing at a significant CAGR owing to technological advancements in cervical cancer diagnostic equipment and procedures. Moreover, unsafe sex with HPV-positive patients, lifestyle changes such as smoking, and obesity are also anticipated to upsurge the revenue of Europe cervical cancer test market over the forecast period. However, increase in the prevalence of cervical cancer in Europe region expected to drive the Europe cervical cancer test market. For instance, according to International Agency for Research on Cancer 2012, the incidence rate of cervical cancer is 13.4 per 100,000 people and mortality rate is 4.9 per 100,000 people. However, mortality is decreasing owing to increase in the technological advancements of disease diagnostics and launching of low-cost test such as Visual Inspection with Acetic acid (VIA) test. Moreover, acquisitions and mergers and diversification of business segments are the strategies followed by the market players to increase their revenue in Europe cervical cancer test market. For instance, in July 2011, Roche has acquired mtm laboratories AG for the expansion of Cervical Cancer Test Market in the Europe region.
According to World Health Organization Europe, approximately 28,000 women die from cervical cancer every year in the Europe region. The prevalence rate is higher in Germany, France, and U.K. (according to cancer research UK 2014, about 3,224 new cervical cancer cases were diagnosed in the U.K.). Due to change in lifestyles such as smoking, unsafe sex, and high adoption of technologically advanced diagnostic tests are anticipated to fuel the Europe cervical cancer test market. Moreover, government initiations for creating awareness about the cervical cancer diagnostic tests and increase in R&D investment for the innovation of novel technologies also expected to propel the Europe cervical cancer test market over the forecast period.
Some of the players in Europe cervical cancer test market are F. Hoffmann La Roche Ltd. (Switzerland), Abbott Diagnostics (U.S.), Oncognostics GmbH (Germany), Becton, Dickinson and Company (U.S.), Randox Laboratories Ltd. (U.K.), Epigenomics AG (Germany), Beckman Coulter (U.S.), and Fujirebio Diagnostics, Inc. (U.S.) to name a few.
- In April 2017, Roche launched the Cobas HPV assay for use on Cobas 8800 and Cobas 6600 systems for the screening of cervical cancer in countries accepting CE mark approval
- In September 2016, Oncognostics developed GynTect 2.0 test used in the early detection of cervical cancer which received CE IVD mark in the European market in 2015
- In September 2014, Abbott launched Real-time high-risk HPV test in the Europe for the primary screening of cervical cancer
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario